South San Francisco, United States
PACT Pharma, a privately held biotechnology company founded in 2016, is focused on developing personalized T cell therapies for cancer. Their mission is to create potentially curative treatments tailored specifically for each patient, with an emphasis on solid tumors.
The company is pioneering non-viral, precision-genome engineered, tumor-specific T-cell therapies, envisioning a world where personalized cancer treatment is accessible to all. Headquartered in the United States, PACT Pharma operates in the Biotechnology, Health Care, and Pharmaceutical industries.
With a strong leadership team and a collaborative culture, they foster an environment of teamwork, humility, and innovation, positioning themselves as a key player in cancer treatment. Their most recent substantial funding was a $75.00M Series C round in January 2020, backed by prominent investors including Casdin Capital, GV, Wu Capital, and AbbVie Ventures among others.
